KR20130052740A - c-Met 억제제로서 6-(1-메틸-1H-피라졸-4-일)-3-(2-메틸-2H-인다졸-5-일티오)-[1,2,4]트리아졸로[4,3-B]피리다진 - Google Patents

c-Met 억제제로서 6-(1-메틸-1H-피라졸-4-일)-3-(2-메틸-2H-인다졸-5-일티오)-[1,2,4]트리아졸로[4,3-B]피리다진 Download PDF

Info

Publication number
KR20130052740A
KR20130052740A KR1020137002382A KR20137002382A KR20130052740A KR 20130052740 A KR20130052740 A KR 20130052740A KR 1020137002382 A KR1020137002382 A KR 1020137002382A KR 20137002382 A KR20137002382 A KR 20137002382A KR 20130052740 A KR20130052740 A KR 20130052740A
Authority
KR
South Korea
Prior art keywords
compound
cancer
methyl
compounds
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137002382A
Other languages
English (en)
Korean (ko)
Inventor
지페이 우
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20130052740A publication Critical patent/KR20130052740A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020137002382A 2010-07-30 2011-07-22 c-Met 억제제로서 6-(1-메틸-1H-피라졸-4-일)-3-(2-메틸-2H-인다졸-5-일티오)-[1,2,4]트리아졸로[4,3-B]피리다진 Ceased KR20130052740A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36933510P 2010-07-30 2010-07-30
US61/369,335 2010-07-30
PCT/US2011/044926 WO2012015677A1 (en) 2010-07-30 2011-07-22 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5-

Publications (1)

Publication Number Publication Date
KR20130052740A true KR20130052740A (ko) 2013-05-23

Family

ID=44513148

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137002382A Ceased KR20130052740A (ko) 2010-07-30 2011-07-22 c-Met 억제제로서 6-(1-메틸-1H-피라졸-4-일)-3-(2-메틸-2H-인다졸-5-일티오)-[1,2,4]트리아졸로[4,3-B]피리다진

Country Status (15)

Country Link
US (1) US8268836B2 (cg-RX-API-DMAC10.html)
EP (1) EP2598144B1 (cg-RX-API-DMAC10.html)
JP (1) JP5738412B2 (cg-RX-API-DMAC10.html)
KR (1) KR20130052740A (cg-RX-API-DMAC10.html)
CN (1) CN103002898A (cg-RX-API-DMAC10.html)
AR (1) AR085183A1 (cg-RX-API-DMAC10.html)
AU (1) AU2011282973B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013002211A2 (cg-RX-API-DMAC10.html)
CA (1) CA2805494A1 (cg-RX-API-DMAC10.html)
EA (1) EA201270818A1 (cg-RX-API-DMAC10.html)
ES (1) ES2516940T3 (cg-RX-API-DMAC10.html)
IN (1) IN2012MN02924A (cg-RX-API-DMAC10.html)
MX (1) MX2013001247A (cg-RX-API-DMAC10.html)
TW (1) TWI431008B (cg-RX-API-DMAC10.html)
WO (1) WO2012015677A1 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2869316C (en) * 2012-05-09 2016-12-20 Eli Lilly And Company Anti-c-met antibodies
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术(太仓)有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10386376B2 (en) 2015-11-09 2019-08-20 Jeimei, Llc Sample container with integrated test strip
CN108853108A (zh) * 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728017B2 (en) * 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CN101553490A (zh) * 2006-10-23 2009-10-07 Sgx药品公司 用作蛋白激酶调节剂的二环三唑类化合物
BRPI0717320A2 (pt) 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
EA016527B1 (ru) 2006-10-23 2012-05-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Триазолопиридазиновые модуляторы протеинкиназ
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA

Also Published As

Publication number Publication date
ES2516940T3 (es) 2014-10-31
TWI431008B (zh) 2014-03-21
EA201270818A1 (ru) 2013-05-30
US8268836B2 (en) 2012-09-18
JP2013532687A (ja) 2013-08-19
BR112013002211A2 (pt) 2016-05-24
AR085183A1 (es) 2013-09-18
WO2012015677A9 (en) 2012-12-13
EP2598144A1 (en) 2013-06-05
MX2013001247A (es) 2013-03-18
WO2012015677A1 (en) 2012-02-02
IN2012MN02924A (cg-RX-API-DMAC10.html) 2015-06-12
AU2011282973B2 (en) 2014-03-20
AU2011282973A1 (en) 2013-01-10
CN103002898A (zh) 2013-03-27
EP2598144B1 (en) 2014-08-13
JP5738412B2 (ja) 2015-06-24
US20120028984A1 (en) 2012-02-02
CA2805494A1 (en) 2012-02-02
TW201219393A (en) 2012-05-16

Similar Documents

Publication Publication Date Title
AU2011282973B2 (en) 6-(1-methyl-1H-pyrazol-4-yl)-3-(2-methyl-2H-indazol -5-ylthio)-[1,2,4] triazolo [4,3-b]pyridazine as a c-Met inhibitor
JP7240784B2 (ja) 8,9-ジヒドロイミダゾール[1,2-a]ピリミド[5,4-e]ピリミジン-5(6H)-ケトン類化合物
EP2850082B1 (en) 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer
CN107709305B (zh) 新型化合物
EP3546460B1 (en) Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method and use thereof
WO2018017983A1 (en) Compounds useful for treating disorders related to ret
EP4592289A1 (en) Novel prmt5 inhibitor and use thereof
WO2014135028A1 (zh) 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
US20250074908A1 (en) Salt of rock inhibitor, crystal form of salt, composition, and pharmaceutical use
WO2012138809A1 (en) Heterocyclic compounds as kinase inhibitors
CN111763215A (zh) 一种具有含氮杂环结构的化合物及其制备方法和用途
CN109641902B (zh) 可用作人pde1抑制剂的三唑并吡嗪酮衍生物
CN103502239A (zh) 可用作脾酪氨酸激酶(syk)抑制剂的吡啶基-和吡嗪基-甲基氧基-芳基衍生物
Zhao et al. Discovery of thieno [3, 2-c] pyridin-4-amines as novel Bruton’s tyrosine kinase (BTK) inhibitors
WO2019029629A1 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES FOR USE AS KINASE INHIBITORS
CN113527300A (zh) 布鲁顿酪氨酸蛋白激酶抑制剂
CN113717245A (zh) 含有2,8,9-三取代-9h-嘌呤结构片段的egfr降解剂及其盐和应用
CN121925419A (zh) 一种吡啶-2(1h)-酮类prmt5-mta抑制剂、其药物组合物及其应用
EP3661936B1 (en) [1,2,4]triazolo[4,3-a]pyrazin-6(5h)-one derivatives
JP7053654B2 (ja) PI3Kβ阻害剤としてのキノキサリン及びピリドピラジン誘導体
CN113527311B (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
AU2023256032A1 (en) Crystal of 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
CN110078732A (zh) 嘌呤类化合物及其用途
CN119080781A (zh) 取代的咪唑并喹喔啉化合物及其应用
KR100714370B1 (ko) 항종양 활성을 갖는〔1,2,4〕―트리아졸로〔4,3―c〕퀴나졸린 유도체

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20130129

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130129

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140623

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20141002

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140623

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I